文献速递造血干细胞移植与细胞治疗

造血干细胞移植受者接种SARS-CoV-2疫苗后抗体检测的前瞻性研究

SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
PubMed 文献 · Am J Hematol · 2021-11-02

这项多中心前瞻性观察研究纳入397例造血干细胞移植受者,其中异基因311例、自体86例,在完成SARS-CoV-2疫苗接种后3-6周监测抗体。异基因和自体移植受者中可检测到SARS-CoV-2反应性抗体的比例分别为78%和85%。多因素分析显示,异基因移植中淋巴细胞减少、活动性GVHD和移植后第一年内接种与抗体检测率降低相关;自体移植中非霍奇金淋巴瘤和活动性皮质类固醇治疗与较低检测率相关。

要点

  • 异基因和自体移植受者接种疫苗后抗体检测率分别为78%和85%。
  • 异基因移植中淋巴细胞<1×10^9/ml、活动性GVHD和移植后1年内接种降低抗体检测率。
  • 自体移植中非霍奇金淋巴瘤和活动性皮质类固醇治疗降低抗体检测率。

核心结论

  • 在这些严重免疫抑制患者中观察到令人鼓舞的SARS-CoV-2反应性抗体检测率。
  • 异基因移植中淋巴细胞减少、GVHD和接种时机,自体移植中NHL和皮质类固醇治疗应被考虑用于识别需要SARS-CoV-2抗体监测的候选者。

研究设计与样本

  • 多中心前瞻性观察研究,纳入397例造血干细胞移植受者,其中异基因311例、自体86例。
  • 监测时间为完成SARS-CoV-2疫苗接种后3-6周,接种时间范围为2021年2月1日至2021年7月20日。
  • 大多数患者(387例,97.4%)接种mRNA疫苗,93%的受者在移植后1年以上接种。

主要发现

  • 异基因移植受者中242例(78%)可检测到SARS-CoV-2反应性抗体,自体移植受者中73例(85%)可检测到。

临床怎么用

  • 对于异基因移植受者,若存在淋巴细胞减少、活动性GVHD或移植后1年内接种,应考虑进行SARS-CoV-2抗体监测。
  • 对于自体移植受者,若患非霍奇金淋巴瘤或正在接受活动性皮质类固醇治疗,应考虑进行SARS-CoV-2抗体监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia < 1 × 109 /ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16-0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27-0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15-0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR 0.09, 95% CI 0.02-0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02-0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Piñana JL, López-Corral L, Martino R, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2021. PMID: 34695229. doi:10.1002/ajh.26385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。